 PLANEGGMUNICH, GERMANY ACCESSWIRE March 2, 2021 MorphoSys AG FSE:MOR; Prime Standard Segment; MDAX TecDAX; NASDAQ:MOR, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmithKline plc LSENYSE: GSK reported preliminary results of the OSCAR Otilimab in Severe COVID-19 Related Disease study using otilimab formerly MOR103GSK3196165 for the treatment of severe pulmonary COVID-19 related disease. Given these data suggest an important clinical benefit in a pre-defined sub-group of high-risk patients and the urgent public health need, GSK has amended the OSCAR study to expand this cohort to confirm these potentially significant findings. 